BeiGene
BGNE
$181.18
Share price
-1.62%
Change (1 day)
6.75%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) Fails to deliver data
Key failure to deliver metrics for BeiGene :
- Last SEC data release: 2023-07-31
- Last 15 days FTD volume: $2.99 M
- Last 3 months FTD volume: $18.38 M
- Last year FTD volume: $93.75 M
Failures to deliver for BeiGene (BGNE) - 3 month history
Number of shares, 3 month chartBiweekly Failures to deliver volume for BeiGene (BGNE) - since 2016
Volume in USD (price x number of shares), data since 2016BeiGene (BGNE) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2023 | $36.83 M | -62.71% |
| 2022 | $98.76 M | 113.17% |
| 2021 | $46.33 M | -62.37% |
| 2020 | $0.12 B | 40.02% |
| 2019 | $87.92 M | 48.77% |
| 2018 | $59.1 M | 255.99% |
| 2017 | $16.6 M | 169.67% |
| 2016 | $6.15 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 OPKO Health
OPK | $1.25 M | $7.12 M | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $0.05 M | $0.27 M | 🇺🇸 USA |